Official Title
The Registry of Oncology Outcomes Associated With Testing and Treatment (ROOT)
Brief Title
The Registry of Oncology Outcomes Associated With Testing and Treatment
Protocol ID
NCT04028479
Lead Sponsor
Taproot Health
Brief Summary
This study is to collect and validate regulatory-grade real-world data (RWD) in oncology
using the novel, Master Observational Trial construct. This data can be then used in
real-world evidence (RWE) generation. It will also create reusable infrastructure to
allow creation or affiliation with many additional RWD/RWE efforts both prospective and
retrospective in nature.
Detailed Description
This is a master observational trial (MOT). Anyone who has been diagnosed with advanced
cancer is eligible as long as they are a candidate for treatment. Each patient will
receive testing and treatment as determined by patient in consultation with physician.
ROOT will proceed in two directions: (1) Validation Cohorts. These patients will
demonstrate the ability of the MOT to prospectively collect data using the same protocol
and related documents, standardized data elements and processes, and accepted scientific
endpoints; and (2) Analysis Cohorts. The modular nature of the study allows collection of
RWD ranging from diagnosis only to the full treatment course of the of the patient.
Patients are grouped to allow focused data collection or a specific analysis. Analysis
cohorts can be created from patients already enrolled in ROOT or be defined
prospectively. Because of the ongoing advancements of molecular based oncology, this
trial allows a detailed focus on molecular testing as part of any cohort.
Data is reported by the group that is most qualified to provide this information and is
proved, at point of care, using standardized data elements and processes. Physicians will
report diagnosis, molecular characteristics, staging, disease burden, significant
comorbidities, treatment response, and medical decision making. Molecular testing
(reports and details) will be requested from testing laboratories. Any diagnostic films
will be received digitally from the location the study was performed. Research staff
assist in data entry and providing physicians needed data as part of the regular workflow
to allow point-of-care reporting.
The Validation Cohorts and Analysis Cohorts may run sequentially or in parallel with each
other.
Study Period
-
Enrollment Count
167 participants
Eligibility Criteria
Inclusion Criteria:
- Patient or representative provides written informed consent
- Patient is diagnosed with advanced malignancy
- Patient is willing to be treated for this malignancy according to a plan determine
by them and their physician
- patient will be willing to have regular follow up visits as part of their standard
of care
Exclusion Criteria:
- patient is not a candidate or does not desire any treatment for their disease
Filters
Adenocarcinoma
Adenocystic Carcinoma
Anal Cancer
Appendix Cancer
Brain Tumor
Glioblastoma
Astrocytoma
Bile Duct Cancer
Cholangiocarcinoma
Bladder Cancer
Bone Cancer
Synovial Sarcoma
Chondrosarcoma
Liposarcoma
Sarcoma, Kaposi
Sarcoma,Soft Tissue
Sarcoma
Osteosarcoma
CNS Cancer
Brain Stem Neoplasms
Breast Cancer
Cervical Cancer
Colorectal Cancer
Rectal Cancer
Colon Cancer
Esophageal Cancer
Esophagus Cancer
Cancer of Colon
Pancreatic Cancer
Cancer of Pancreas
Testis Cancer
Testicular Cancer
Ureter Cancer
Renal Cell Carcinoma
Kidney Cancer
Gestational Trophoblastic Tumor
Head and Neck Neoplasms
Parotid Tumor
Larynx Cancer
Tongue Cancer
Pharynx Cancer
Salivary Gland Cancer
Acute Myeloid Leukemia
Chronic Myeloid Leukemia
Acute Lymphoblastic Leukemia
Multiple Myeloma
Non Hodgkin Lymphoma
Carcinoid Tumor
Lung Cancer
Neuroendocrine Tumors
Mesothelioma
Thyroid Cancer
Parathyroid Neoplasms
Adrenal Cancer
Small Bowel Cancer
Stomach Cancer
Liver Cancer
Hepatic Cancer
Melanoma
Skin Cancer
Unknown Primary Tumors
Uterine Cancer
Fallopian Tube Cancer
Ovarian Cancer
Prostate Cancer
Vaginal Cancer
Penile Cancer
Vulvar Cancer
Waldenstrom Macroglobulinemia
Cancer, Advanced
Thymus Cancer
Nasopharyngeal Carcinoma
Multiple Endocrine Neoplasia
Pheochromocytoma
Small Cell Carcinoma
Pulmonary Carcinoma
COMPLETED
ADULT
OLDER_ADULT